EPO906 Therapy in Patients With Advanced Kidney Cancer
This study will examine whether the investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause kidney cancer.
Kidney Neoplasms
DRUG: epothilone b
Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST), every 8 weeks
Objective response rate (ORR), every 8 weeks|Time to disease progression (TTP), every 8 weeks|Overall Survival (OS), every 8 weeks|Safety and tolerability of EPO906, at each visit|Tumor-specific mutations and gene expression changes in tumor cells with blood cells and plasma, For biomarker development, prior to the first treatment with EPO906, on the day of any clinically indicated tumor biopsy/resection and on the day of each tumor assessment
This study will examine whether the investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause kidney cancer.